ArticleBreast cancer research : BCR2024

Promoter profiles in plasma CfDNA exhibits a potential utility of predicting the efficacy of neoadjuvant chemotherapy in breast cancer patients.

Xu Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.